Whalesbook
Commerce Secretary Rajesh Agrawal is pushing India's pharmaceutical industry towards greater self-sufficiency, aiming for significantly higher domestic production of essential drugs, Active Pharmaceutical Ingredients (APIs), and intermediates. This push is driven by global supply chain concerns and geopolitical instability. While the sector has shown resilience, meeting such a high domestic production target presents major operational and financial challenges.
The directive aims for India to produce 80-90% of its pharmaceutical needs locally. This comes as India, a global leader in drug volume, exported $30.47 billion in FY2024-25. However, the country heavily relies on imports for key raw materials. China supplies a significant portion, around 70-74%, of India's API imports, and even higher for some essential medicines. This reliance poses risks like supply disruptions and price hikes. To counter this, the government has launched schemes like the Production Linked Incentive (PLI) with substantial funding for API and drug intermediate manufacturing, alongside developing dedicated bulk drug parks.
Major Indian drugmakers like Sun Pharmaceutical Industries (P/E ~36.96), Cipla Ltd. (P/E ~21.21), and Dr. Reddy's Laboratories (P/E ~17.29) are increasingly focusing on higher-value areas such as biologics and biosimilars, which are expected to drive future growth. The Indian biologics market is projected to reach $12 billion by 2025, with a projected Compound Annual Growth Rate (CAGR) of 22%, and the biosimilar market is also expanding rapidly.
Achieving the 80-90% self-reliance target faces substantial obstacles beyond policy. The capital investment needed for new API manufacturing facilities is immense, potentially billions of dollars. While PLI schemes are attracting investment, bulk drug parks are not expected to be fully operational until 2026, meaning import reliance will continue in the meantime. India excels in generic formulations but lags in complex APIs where China and other nations hold a technological lead. Indigenous production of basic bulk drugs might struggle to compete with established Chinese suppliers without ongoing subsidies.
Even domestically produced APIs often rely on China for essential starting materials (KSMs), with estimates suggesting 60-90% are sourced from China. Delays in executing government initiatives, including land acquisition and environmental clearances, slow down progress. Current geopolitical instability, especially in the Middle East, has driven input costs up by 200-300% for some raw materials and packaging, potentially squeezing margins for companies facing price caps on medicines.
Analysts predict the Indian pharmaceutical sector will see 7-9% revenue growth in FY2026, fueled by domestic demand and steady European exports. Operating profit margins are expected to remain stable around 24-25%. R&D spending will likely continue at 6-7% of revenue, with a greater focus on complex molecules. Government initiatives like 'Biopharma SHAKTI' aim to boost the biologics sector, targeting a 5% share of the global market. This strategic investment in infrastructure and innovation could enhance India's global position, provided the challenges in API production and supply chain resilience are effectively managed.